A genetic mutation that causes a change in the KRAS pathway appears to be linked to higher likelihood of platinum resistance in women with ovarian cancer. The KRAS pathway is active in other types of tumors, including colorectal.
Read the article here
See the abstract of the study here
The post Mutation in KRAS Gene May Indicate Drug Resistance in Ovarian Cancer Patients appeared first on Ovarian Cancer National Alliance.
